CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 460 enrolled
Drug / intervention
DMPA +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03255941
NCT03255941Early Ph 1Completed

'A Randomized Controlled Trial of Safety and Effectiveness of Depo Provera Intramuscular and Subcutaneous Administration Comparing Lay Lady Health Workers With Clinically-trained Family Welfare Workers in Pakistan

FHI 360·interventional·Posted Aug 21, 2017·Updated Apr 13, 2021

In Brief

A Early Phase 1 clinical trial evaluating DMPA and Sayana Press for Contraception. Completed, enrolled 460 participants across 1 site.

Detailed Summary

This is a randomized controlled trial comparing lay Lady Health Workers (Lay Health Workers) with Family Welfare Workers (Clinically- trained Health Workers) on quantitative measures of safety and effectiveness of Depo Provera and Sayana Press provision in a clinic setting. This comparative trial will test the non-inferiority hypothesis that Lady Health Workers are just as competent as clinically-trained Family Welfare Workers in screening and counseling first-time injectable users. These first time users will also be randomly assigned to receive intramuscular or subcutaneous injections of DMPA.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsContraception
CountriesPakistan

Timeline

Early Ph 1CompletedFinished
201820192020202120222023202420252026
First PostedAug 21, 2017
Enrollment StartMar 19, 2018
Primary CompletionJul 15, 2018
Study CompletionJul 23, 2018
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 8.9 years ago

Interventions

DMPAdrug

The safety and effectiveness of provision of injectable contraception will be compared between providers' screening and counseling for eligibility to use DMPA.

Sayana Pressdrug

The safety and effectiveness of provision of injectable contraception will be compared between providers' screening and counseling for eligibility to use Sayana Press